These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 31275681)

  • 1. Use of Ceftolozane/Tazobactam in a Case of Septic Shock by Puerperal Sepsis.
    Pezzi M; Scozzafava AM; Giglio AM; Vozzo R; Casella PD; Tiburzi SP; Cosco L; Verre M
    Case Rep Obstet Gynecol; 2019; 2019():8463693. PubMed ID: 31275681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials.
    Popejoy MW; Paterson DL; Cloutier D; Huntington JA; Miller B; Bliss CA; Steenbergen JN; Hershberger E; Umeh O; Kaye KS
    J Antimicrob Chemother; 2017 Jan; 72(1):268-272. PubMed ID: 27707990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ESBLs and resistance to ceftazidime/avibactam and ceftolozane/tazobactam combinations in Escherichia coli and Pseudomonas aeruginosa.
    Ortiz de la Rosa JM; Nordmann P; Poirel L
    J Antimicrob Chemother; 2019 Jul; 74(7):1934-1939. PubMed ID: 31225611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012).
    Sader HS; Farrell DJ; Flamm RK; Jones RN
    J Infect; 2014 Sep; 69(3):266-77. PubMed ID: 24780763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of ceftolozane-tazobactam against Gram-negative pathogens isolated from lower respiratory tract infections in the Asia-Pacific region: SMART 2015-2016.
    Kuo SC; Liu CE; Lu PL; Chen YS; Lu MC; Ko WC; Hsueh PR; Chuang YC; Wang FD;
    Int J Antimicrob Agents; 2020 Mar; 55(3):105883. PubMed ID: 31923574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Enterobacteriaceae Isolates Producing Extended-Spectrum β-Lactamases from U.S. Hospitals.
    Castanheira M; Doyle TB; Mendes RE; Sader HS
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31085510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Puerperal septic shock and necrotizing fasciitis caused by
    Koo YJ
    Yeungnam Univ J Med; 2018 Dec; 35(2):248-252. PubMed ID: 31620604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study.
    Tato M; García-Castillo M; Bofarull AM; Cantón R;
    Int J Antimicrob Agents; 2015 Nov; 46(5):502-10. PubMed ID: 26315199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
    Alatoom A; Elsayed H; Lawlor K; AbdelWareth L; El-Lababidi R; Cardona L; Mooty M; Bonilla MF; Nusair A; Mirza I
    Int J Infect Dis; 2017 Sep; 62():39-43. PubMed ID: 28610832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In Vitro Activity of Ceftolozane Alone and in Combination with Tazobactam against Extended-Spectrum-β-Lactamase-Harboring Enterobacteriaceae.
    Melchers MJ; van Mil AC; Mouton JW
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4521-5. PubMed ID: 25987635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and safety of tazobactam/ceftolozane in combination with metronidazole in Japanese patients with complicated intra-abdominal infections.
    Mikamo H; Monden K; Miyasaka Y; Horiuchi T; Fujimoto G; Fukuhara T; Yoshinari T; Rhee EG; Shizuya T
    J Infect Chemother; 2019 Feb; 25(2):111-116. PubMed ID: 30528561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of ceftolozane/tazobactam in combination with other classes of antibacterial agents.
    Jacqueline C; Howland K; Chesnel L
    J Glob Antimicrob Resist; 2017 Sep; 10():326-329. PubMed ID: 28689923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceftolozane/tazobactam for the treatment of complicated intra-abdominal infections.
    Eckmann C; Solomkin J
    Expert Opin Pharmacother; 2015 Feb; 16(2):271-80. PubMed ID: 25529765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI).
    Solomkin J; Hershberger E; Miller B; Popejoy M; Friedland I; Steenbergen J; Yoon M; Collins S; Yuan G; Barie PS; Eckmann C
    Clin Infect Dis; 2015 May; 60(10):1462-71. PubMed ID: 25670823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
    Castanheira M; Duncan LR; Mendes RE; Sader HS; Shortridge D
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro pharmacodynamic evaluation of ceftolozane/tazobactam against β-lactamase-producing Escherichia coli in a hollow-fibre infection model.
    Soon RL; Lenhard JR; Bulman ZP; Holden PN; Kelchlin P; Steenbergen JN; Friedrich LV; Forrest A; Tsuji BT
    Int J Antimicrob Agents; 2017 Jan; 49(1):25-30. PubMed ID: 27931793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of tazobactam/ceftolozane in Japanese patients with uncomplicated pyelonephritis and complicated urinary tract infection.
    Arakawa S; Kawahara K; Kawahara M; Yasuda M; Fujimoto G; Sato A; Yokokawa R; Yoshinari T; Rhee EG; Aoyama N
    J Infect Chemother; 2019 Feb; 25(2):104-110. PubMed ID: 30420153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating vancomycin and piperacillin-tazobactam in ED patients with severe sepsis and septic shock.
    Le C; Chu F; Dunlay R; Villar J; Fedullo P; Wardi G
    Am J Emerg Med; 2018 Aug; 36(8):1380-1385. PubMed ID: 29321120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful Use of Ceftolozane-Tazobactam to Treat a Pulmonary Exacerbation of Cystic Fibrosis Caused by Multidrug-Resistant Pseudomonas aeruginosa.
    Vickery SB; McClain D; Wargo KA
    Pharmacotherapy; 2016 Oct; 36(10):e154-e159. PubMed ID: 27522066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Severe sepsis and septic shock by Escherichia coli, clinical and microbiological analysis in Medellin, Colombia].
    Restrepo-Álvarez CA; Bernal E; Ascuntar-Tello J; Jaimes F
    Rev Chilena Infectol; 2019 Aug; 36(4):447-454. PubMed ID: 31859768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.